ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
63 announcements with these filters
Anondita Medicare reported a consolidated total income of ₹138.26 Crore for FY2026. The company achieved a consolidated net profit of ₹34.30 Crore during the period.
Anondita Medicare secured a ₹0.04 Crore international order from S.S.R Traders for condom supplies. The contract features a 4-6 week execution period from advance receipt.
Anondita Medicare Limited re-submitted audited financial results to rectify clerical errors in profit allocation and EPS. Reported net profit and overall financial position remain unchanged.
Anondita Medicare secured a massive ₹5,16,024 Crore condom supply order from Nepal's Lotus Pharmaceuticals. Delivery is scheduled within six weeks of advance payment.
Anondita Medicare Limited secured a ₹0.05 Crore condom supply order from Nepal-based Lotus Pharmaceuticals. Delivery is scheduled within 4-6 weeks following advance payment receipt.
Anondita Medicare Limited received a BWR BBB/Stable rating for its ₹56.21 Crore bank facilities. This assignment reflects the company's established market position and stable financial outlook.
Anondita Medicare (formerly Anondita Healthcare) reported strong FY26 performance, achieving ₹137.4cr revenue and ₹34.3cr PAT. Strategy focuses on expanding high-margin female condom production and global exports.
Anondita Medicare Limited secured a ₹71.84 Crore supply order from the Ministry of Health. This domestic government contract significantly enhances the company's revenue visibility.
Anondita Medicare secured a ₹7.18 Crore purchase order from the Ministry of Health for condom supplies. The contract execution spans 180 days in two tranches.
Anondita Medicare reported FY26 revenue of ₹137.42 Crore and 108% PAT growth. Strong operational momentum and margin expansion drove robust year-on-year financial performance.
Anondita Medicare issued a second corrigendum to its EGM notice regarding revised warrant pricing. The update reflects changes in valuation following a revised 90-day trading period calculation.
Anondita Medicare reported no deviations in its ₹69.49 Crore IPO proceeds utilization. Reallocations were made to fund higher working capital requirements via shareholder approval.
Anondita Medicare Ltd reported revenue from operations of ₹83.3 Cr (+82.7% YoY) and net profit of ₹21.3 Cr (+102.9% YoY) for H2 FY26.
Anondita Medicare Limited reported audited annual results for the period ended March 31, 2026. The board approved both standalone and consolidated financial statements during the session.
Anondita Medicare issued a corrigendum for its upcoming EGM regarding a ₹29.58 Crore preferential warrant issue. Key changes include revised relevant dates and updated valuation details.
Anondita Medicare Limited scheduled a board meeting on May 22, 2026, to consider audited financial results. The trading window remains closed until 48 hours post-results.
Anondita Medicare Limited convened an EGM for May 28, 2026, to approve ₹137.59 Crore in related party transactions and preferential warrant issuance to promoters.
Anondita Medicare Limited submitted its IPO monitoring report for quarters ended December 2025 and March 2026. Total IPO proceeds of ₹69.49 Crore are being monitored.
Anondita Medicare Limited will participate in Pharma Eurasia 2026, Uzbekistan this May. The event aims to expand market presence and engage potential buyers in Central Asia.
Anondita Medicare Limited has convened an EGM for May 28, 2026, to approve a ₹29.13 Crore preferential issue of convertible warrants to promoters. Other agenda items include material related party transactions and an increase in managerial remuneration for the Managing Director and Whole-Time Director.
Anondita Medicare Limited's board approved a ₹29.13 Crore preferential issue of 2,85,000 convertible warrants to promoter Mr. Anupam Ghosh. The board also approved material related party transactions, an object clause alteration, and increased remuneration for top management. These strategic moves aim to strengthen capital and align operations for FY 2026-27.
Anondita Medicare Limited has approved a preferential issuance of 2,85,000 warrants to Mr. Anupam Ghosh (Promoter and MD) for ₹29.13 Crore. The warrants, priced at ₹1,022 each, are convertible into equity shares within 18 months. This capital infusion demonstrates promoter commitment and strengthens the company's financial base.
Anondita Medicare Limited's Board has approved an alteration to its Memorandum of Association's Main Objects. The amendment expands its business scope from male latex contraceptives to include female condoms, sexual wellness, personal care, healthcare products, diagnostic kits, and medical gloves. This strategic shift signals a significant diversification beyond its core condom manufacturing operations.
Anondita Medicare Limited's board approved the preferential issuance of 2,85,000 convertible warrants to promoter Mr. Anupam Ghosh at ₹1022 per warrant, totalling ₹29.13 Crore. The warrants are convertible into equity shares within 18 months, strengthening the company's capital base.
Anondita Medicare Limited's board approved the issuance of warrants to promoters, material related party transactions for FY 2026-27, and an increase in remuneration for its Managing and Whole-Time Directors. The board also called an EGM for shareholder approval of these matters and proposed an alteration to the company's Memorandum of Association.
Anondita Medicare Limited has qualified as a vendor under the South Africa Government Tender (RT75-2025) for public healthcare procurement. The qualification spans five years from November 2025 to October 2030. This achievement follows a successful SABS audit and supports the company's international expansion strategy for its condom manufacturing business.
Anondita Medicare Limited, through its subsidiary, has re-launched its 'COBRA® Shubh Samachar™' pregnancy test kit. The re-launch features enhanced formulation and process optimization to improve efficiency while maintaining pricing. This initiative targets India's growing home-based diagnostics market, aiming to accelerate top-line growth and enhance profitability margins through a scalable product strategy.
Anondita Medicare Limited has been qualified as a vendor for the supply of condoms and lubricants to the South African Government. The empanelment under Transversal Contract RT75-2025 is valid from November 2025 to October 2030. Following this qualification, the company will execute agreements and receive purchase orders from South African local entities.
Anondita Medicare Limited expanded its retail presence in West Bengal, reaching 1,741 touchpoints across Hooghly (411), Asansol (616), and Cooch Behar (714). The company plans further pan-India expansion and future international market entry to diversify revenue streams and improve brand visibility.
Anondita Medicare Limited announced its participation in the 'Nepal Medical Show 2026 (9th Edition)' from April 30 to May 2, 2026. The company aims to expand its presence in South Asian countries and engage with potential buyers. This strategic move focuses on exploring international business opportunities in the healthcare sector.